

06-26-01

06/25/01
U.S. PTO
JC961

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	CM2380
First Inventor	Johan Smets
Assignee	Th Procter & Gamble Company
Title	Detergent Compositions Comprising a Cyclodextrin Transferase Enzyme and a Detergent Ingredient
Express Mail Label No.	EF182965863US

APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

1. Fee Transmittal Form (e.g., PTO/SB/17)
(*Submit an original and a duplicate for fee processing*)
2. Applicant claims small entity status
(see 37 CFR §1.27)
3. Specification Total Pages [94]
(*preferred arrangement set forth below*)
 - Descriptive Title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 USC §113) Total Sheets []
 - 5. Oath or Declaration Total pages [2]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR §1.63(d))
(*for continuation/divisional with Box 18 complete*)
 - i. **DELETION OF INVENTORS**
Signed statement attached deleting inventor(s)
named in the prior application,
see 37 CFR §§1.63(d)(2) and 1.33(b).
 - 6. Application Data Sheet. See 37 CFR §1.76
7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(*if applicable, all necessary*)
 - a. Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. Paper
 - c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement Power of Attorney
(*when there is an assignee*)
11. English Translation Document (*if applicable*)
12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503)
(*Should be specifically itemized*)
15. Certified Copy of Priority Document(s)
(*if foreign priority is claimed*)
16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. Other:

18. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR §1.76: Continuation Divisional Continuation-in-part (CIP)

of prior application No. /

Group/Art Unit: _____

Prior application information: Examiner: _____

For **CONTINUATION OR DIVISIONAL APPS** only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.**19. CORRESPONDENCE ADDRESS**

NAME	Frank Taffy The Procter & Gamble Company			
ADDRESS	Miami Valley Laboratories P.O. Box 538707			
CITY	Cincinnati	STATE	Ohio	ZIP CODE
COUNTRY	U.S.A.	TELEPHONE	513/627-1888	FAX

Name (Print/Type)	Richard S. Echler, Sr.	Registration No. (Attorney/Agent)	41,006
Signature		Date	25 JUN 01

+

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

Complete if Known

Application Number

Confirmation Number

Filing Date

First Named Inventor

Examiner Name

Group/Art Unit

TOTAL AMOUNT OF PAYMENT (\$)**710.00**

Attorney Docket No..

CM2380

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number **16-2480**Deposit Account Name **The Procter & Gamble Company**

Charge Any Additional Fee Required Under status. See 37 CFR §127
37 C.F.R. §§1.16 and 1.17

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Code	(\$)	Fee Description	Fee Paid
105	130	Surcharge-late filing fee or oath	<input type="checkbox"/>
127	50	Surcharge-late provisional filing fee or cover sheet	<input type="checkbox"/>
139	130	Non-English specification	<input type="checkbox"/>
147	2,520	For filing a request for <i>ex parte</i> reexamination	<input type="checkbox"/>
112	920*	Requesting publication of SIR prior to Examiner's action	<input type="checkbox"/>
113	1,840*	Requesting publication of SIR after Examiner's action	<input type="checkbox"/>
115	110	Extension for reply within 1 st month	<input type="checkbox"/>
116	390	Extension for reply within 2 nd month	<input type="checkbox"/>
117	890	Extension for reply within 3 rd month	<input type="checkbox"/>
118	1,390	Extension for reply within 4 th month	<input type="checkbox"/>
128	1,890	Extension for reply within 5 th month	<input type="checkbox"/>
119	310	Notice of Appeal	<input type="checkbox"/>
120	310	Filing a brief in support of an appeal	<input type="checkbox"/>
121	270	Request for oral hearing	<input type="checkbox"/>
138	1,510	Petition to institute a public use proceeding	<input type="checkbox"/>
140	110	Petition to revive - unavoidable	<input type="checkbox"/>
141	1,240	Petition to revive - unintentional	<input type="checkbox"/>
142	1,240	Utility issue fee (or reissue)	<input type="checkbox"/>
143	440	Design issue fee	<input type="checkbox"/>
144	600	Plant issue fee	<input type="checkbox"/>
122	130	Petitions to the Commissioner	<input type="checkbox"/>
123	50	Petitions related to provisional applications	<input type="checkbox"/>
126	180	Submission of Information Disclosure Statement	<input type="checkbox"/>
146	710	Filing a submission after final rejection (37 CFR § 1.129(a))	<input type="checkbox"/>
149	710	For each additional invention to be examined (37 CFR § 1.129(b))	<input type="checkbox"/>
179	710	Request for Continued Examination (RCE)	<input type="checkbox"/>
169	710	Request for expedited examination of a design application	<input type="checkbox"/>
Other fee (specify) _____			<input type="checkbox"/>
Other fee (specify) _____			<input type="checkbox"/>

* Reduced by Basic Filing Fee Paid **SUBTOTAL(3) (\$)-0-**

SUBMITTED BY

Name (Print/Type)	Richard S. Etter, Sr.	Registration No. (Attorney/Agent)	41,006	Complete (if applicable)
Signature		Telephone	(513) 627-0079	Date 25 Jun 01

WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2034.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.